Key Takeaways From Bristol-Myers Squibb Analyst Ratings
Portfolio Pulse from Benzinga Insights
In the past three months, analysts have shown mixed sentiments towards Bristol-Myers Squibb (NYSE:BMY), with recent ratings being somewhat bearish or indifferent. The average 12-month price target has slightly decreased to $44.5. Analysts have adjusted their ratings and price targets in response to market dynamics, reflecting varied expectations for BMY's performance. Despite positive revenue growth, BMY's market capitalization and return on equity lag behind industry peers, though it maintains strong net margins and effective asset utilization.
August 22, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bristol-Myers Squibb (BMY) has received mixed analyst ratings, with a slight decrease in the average price target to $44.5. Analysts have adjusted their ratings in response to market dynamics, reflecting varied expectations for BMY's performance. Despite positive revenue growth, BMY's market capitalization and return on equity lag behind industry peers, though it maintains strong net margins and effective asset utilization.
The mixed analyst ratings and slight decrease in price target suggest a neutral short-term impact on BMY's stock price. While the company shows strong net margins and effective asset utilization, its market cap and ROE lag behind peers, which may temper investor enthusiasm. The varied analyst expectations reflect uncertainty in BMY's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100